You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 19, 2024

Details for New Drug Application (NDA): 214826


✉ Email this page to a colleague

« Back to Dashboard


NDA 214826 describes LOREEV XR, which is a drug marketed by Almatica and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the LOREEV XR profile page.

The generic ingredient in LOREEV XR is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.
Summary for 214826
Tradename:LOREEV XR
Applicant:Almatica
Ingredient:lorazepam
Patents:1
Pharmacology for NDA: 214826
Medical Subject Heading (MeSH) Categories for 214826
Suppliers and Packaging for NDA: 214826
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826 NDA Almatica Pharma LLC 52427-658 52427-658-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (52427-658-30)
LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826 NDA Almatica Pharma LLC 52427-661 52427-661-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (52427-661-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength1MG
Approval Date:Aug 27, 2021TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jan 8, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength2MG
Approval Date:Aug 27, 2021TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jan 8, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength3MG
Approval Date:Aug 27, 2021TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jan 8, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.